文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[F]FAPI-74 PET/CT在特发性肺纤维化中的初步结果。

Initial results with [F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.

作者信息

Mori Yuriko, Kramer Vasko, Novruzov Emil, Mamlins Eduards, Röhrich Manuel, Fernández René, Amaral Horacio, Soza-Ried Cristian, Monje Barbara, Sabbagh Eduardo, Florenzano Matías, Giesel Frederik L, Undurraga Álvaro

机构信息

Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany.

Center for Nuclear Medicine and PET/CT, PositronMed, 7501068, Providencia, Santiago, Chile.

出版信息

Eur J Nucl Med Mol Imaging. 2024 May;51(6):1605-1611. doi: 10.1007/s00259-023-06564-y. Epub 2023 Dec 20.

DOI:10.1007/s00259-023-06564-y
PMID:38117298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11043111/
Abstract

UNLABELLED: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [F]FAPI-74 prospectively in a small patient cohort. METHODS: Eight patients underwent both [F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. RESULTS: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. CONCLUSION: The initial results confirm our assumption that [F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

摘要

未标记：特发性肺纤维化（IPF）是一种预后不良的慢性纤维化间质性肺疾病。由于活化成纤维细胞在肺部纤维化成像中的关键作用，镓标记的FAP配体显示出非常有前景的结果。然而，由于大规模生产，氟标记的FAP配体可能在质量上提供更高的成像结果并带来经济效益。因此，我们试图前瞻性地研究[F]FAPI-74在一小群患者中的潜力。 方法：8名患者接受了[F]FAPI-74-PET/CT和HRCT扫描，然后与没有任何纤维化肺病的对照组进行比较。结合放射学和临床参数分析纤维化肺区域的示踪剂摄取情况。 结果：我们观察到纤维化活性体积、亨氏菲尔德量表以及肺的肺活量和弥散能力之间存在正相关。 结论：初步结果证实了我们的假设，即[F]FAPI-74为IPF患者的肺部纤维化变化提供了一种可行的非侵入性评估方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/fe9b65ccc822/259_2023_6564_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/c74b55d497c2/259_2023_6564_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/9f81df826a9c/259_2023_6564_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/f94e33a69180/259_2023_6564_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/fe9b65ccc822/259_2023_6564_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/c74b55d497c2/259_2023_6564_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/9f81df826a9c/259_2023_6564_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/f94e33a69180/259_2023_6564_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4d4/11043111/fe9b65ccc822/259_2023_6564_Fig4_HTML.jpg

相似文献

[1]
Initial results with [F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.

Eur J Nucl Med Mol Imaging. 2024-5

[2]
Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.

J Nucl Med. 2022-1

[3]
Usefulness of FAPα assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis.

Respir Res. 2023-10-25

[4]
[ Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity.

Eur J Nucl Med Mol Imaging. 2022-9

[5]
Enhanced Detection of Early Pulmonary Fibrosis Disease Using Ga-FAPI-LM3 PET.

Mol Pharm. 2024-7-1

[6]
The Value of F-FDG PET/CT in Evaluating Disease Severity and Prognosis in Idiopathic Pulmonary Fibrosis Patients.

J Korean Med Sci. 2021-10-25

[7]
Tc-Labeled FAPI SPECT Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results.

Pharmaceuticals (Basel). 2023-10-9

[8]
FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.

EClinicalMedicine. 2024-4-10

[9]
Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study.

Lancet Rheumatol. 2021-3

[10]
Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.

J Nucl Med. 2024-4-1

引用本文的文献

[1]
[Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases].

Z Rheumatol. 2025-9-1

[2]
Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.

Mol Imaging Biol. 2025-8-11

[3]
Emerging PET-radiotracers in cardiovascular, neuro-inflammation, lung and rheumatological diseases: a narrative review.

EJNMMI Rep. 2025-8-11

[4]
PET imaging of platelet derived growth factor receptor β in lung fibrosis.

EJNMMI Radiopharm Chem. 2025-7-15

[5]
Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).

Npj Imaging. 2024-11-13

[6]
Comparison of Ga-FAPI-04 and Ga-PSMA in a Case of Interstitial Lung Disease.

Mol Imaging Radionucl Ther. 2025-6-3

[7]
Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis.

Sci Adv. 2025-5-2

[8]
FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases.

Biomedicines. 2025-3-22

[9]
Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.

J Nucl Med. 2025-3-3

[10]
Positron emission tomography an imaging biomarker in pulmonary fibrosis: from therapeutic mechanism to treatment monitoring.

EBioMedicine. 2025-1

本文引用的文献

[1]
Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study.

Lancet Rheumatol. 2021-3

[2]
Ga- or F-FAPI PET/CT-what it can and cannot.

Eur Radiol. 2023-11

[3]
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.

Radiology. 2023-2

[4]
[ Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity.

Eur J Nucl Med Mol Imaging. 2022-9

[5]
Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.

J Nucl Med. 2022-1

[6]
Head-to-head intra-individual comparison of biodistribution and tumor uptake of Ga-FAPI and F-FDG PET/CT in cancer patients.

Eur J Nucl Med Mol Imaging. 2021-12

[7]
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.

Ann Rheum Dis. 2020-7-21

[8]
FAPI-74 PET/CT Using Either F-AlF or Cold-Kit Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients.

J Nucl Med. 2021-2

[9]
The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.

Rheumatology (Oxford). 2020-6-1

[10]
Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

J Nucl Med. 2019-4-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索